再鼎醫藥(09688.HK)隨ADR續漲19% 獲摩通給予「增持」評級
再鼎醫藥(09688.HK)季績後先後獲美銀及摩通維持正面評級。該股連升第二天,今早隨上週五ADR高見26.6元(暫受制10天線26.8元),現報26.1元,續漲19%,成交已有50.8萬股,涉資1,326萬元。再鼎醫藥(ZLAB.US)ADR繼上週五急漲22.7%收33.22美元後,盤後續升0.8%報33.5美元。
摩通基於再鼎首季業績表現,將公司今明兩年經調整每股虧損預測由6.87美元及3.88美元,調整爲僅虧損3.55美元及1.1美元。報告認爲,再鼎定位頗具吸引力,因爲公司產品管道風險較低及其他業務發展具潛力,預期中國行業監管及改革具有長期的推動作用,根據估值變化及營運開支預測等,將H股目標價由105.9元下調至90元,給予「增持」評級。
再鼎醫藥上週公佈,首季虧損按年收窄近65%至8,239.4萬美元,期內總營收按年升逾1.3倍至4,672.4萬美元。美銀證券上週五於季績後重申再鼎「買入」評級,但下調H股目標價逾15%至65.5元,以反映因應上海疫情封城下調公司今年收入預測8%及未來三年盈測3%-15%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.